Articles publicats

Universitat de Girona Plana personal del Dr. Bosch Barrera, Joaquim
Informació general

Publicacions en revistes

    Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A. Menendez  "BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells."  Oncotarget  8 (2017):  35019-35032.
    Bosch-Barrera J; Queralt B; Menendez JA  "Targeting STAT3 with silibinin to improve cancer therapeutics."  Cancer Treatment Reviews   (2017):  61-69.
    Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA  "Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.."  Cell Cycle  16 (2017):  1022-1028.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R  "A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.."  Lung Cancer   (2017):  -.
    Wehler T; Thomas M; Schumann C; Bosch-Barrera J, Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L  "A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.."  Lung Cancer   (2017):  212-216.
    Sais E; Menéndez JA; Bosch-Barrera J  "The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?."  Translational Cancer Research  6 (2017):  S201-S204.
    Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA.  "EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells."  Oncology Reports  38 (2017):  263-270.
    Fernández-Arroyo S; Cuyàs E; Bosch-Barrera J; Alarcón T; Joven J; Menendez JA  "Activation of the methylation cycle in cells reprogrammed into a stem cell-like state.."  Oncoscience  2 (2016):  958-967.
    Bosch-Barrera J; Sais E; Cañete N; Marruecos J; Cuyàs E; Izquierdo A; Porta R; Haro M; Brunet J; Pedraza S; Menendez JA  "Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin."  Oncotarget  7 (2016):  32006-32014.
    de Kock L; Bah I; Brunet J; Druker H; Astigarraga I; Bosch-Barrera J; Soglio DB; Nguyen VH; Malkin D; Priest JR; Foulkes WD.  "Somatic DICER1 mutations in adult-onset pulmonary blastoma."  European Respiratory Journal   (2016):  -.
    Ferreira-Padilla G; Ferrández-Antón T; Lolas-Stepke F; Almeida-Cabrera R; Brunet J; Bosch-Barrera J  "Ethics competences in the undergraduate medical education curriculum: the Spanish experience.."  CMJ: Croatian Medical Journal  57 (2016):  493-503.
    Cuyàs E; Pérez-Sánchez A; Micol V; Menendez JA; Bosch-Barrera J.  "STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.."  Cell Cycle   (2016):  -.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; De Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA.  "Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer."  Oncotarget  7 (2016):  82185-82199.
    Bosch-Barrera J; Holguin F; Baldó X; Rubio M; Porta R; Fuentes R; Teixidó C; Ramirez JL; Ferran N; Sebastián F; Rosell R  "Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression ."  Anticancer Research  35 (2015):  4871-4875.
    Sauri T; Izquierdo À; Ramió-Torrentà L; Sanchez-Montañez À; Bosch-Barrera J; Porta R  "Paraneoplastic Limbic Encephalitis in a Male with Squamous CellCarcinoma of the Lung."  Journal Of Clinical Neurology  11 (2015):  87-91.
    Bosch-Barrera J; Menendez JA.  "Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.."  Cancer Treatment Reviews   (2015):  -.
    Bosch-Barrera J; Briceño García HC; Capella D; De Castro Vila C; Farrés R; Quintanas A; Ramis J; Roca R; Brunet J  "Teaching Bioethics to Students of Medicine with Problem-Based Learning (PBL)."  Cuadernos de Bioética  26 (2015):  303-309.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Vite  "BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.."  Scientific Reports   (2015):  -.
    Cuyàs, E; Martin-Castillo, B; Corominas-Faja, B; Massaguer, A; Bosch-Barrera, J; Menendez, J.A.  "Anti-protozoal and anti-bacterial Antibiotics that inhibit protein synthesis kill Cancer subtypes enriched for stem cell-like properties."  Cell Cycle  14 (2015):  3527-3532.
    Cuyàs, E; Fernández-Arroyo, S; Corominas-Faja, B; Rodríguez-Gallego, E; Bosch-Barrera, J; Martin-Castillo, B; De Llorens, R; Joven, J; Menendez, J.A  "Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype."  Oncotarget  6 (2015):  12279-12296.
    Javier A. Menendez; Rosa Quirantes-Piné; Esther Rodríguez-Gallego; Sílvia Cufí; Bruna Corominas-Faja; Elisabet Cuyàs; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Antonio Segura-Carretero; Jorge Joven  "Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment."  Oncotarget  5 (2014):  2344-2348.
    Bosch-Barrera J; Corominas-Faja B; Cuyàs E; Martin-Castillo B; Brunet J; Menendez JA  "Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient."  Anticancer Research  34 (2014):  4323-4327.
    Vidal J; Clavé S; de Muga S; González I; Pijuan L; Gimeno J; Remón J; Reguart N; Viñolas N; Gironés R; Bernet L;, Majem M; Bosch-Barrera J; Porta R; Alonso N; Palmero R; Taus A; Albanell J; Espinet B; Salido M; Arriola E  "Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients."  Journal of Thoracic Oncology  9 (2014):  1816-1820.
    Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R  "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma."  Lung Cancer  86 (2014):  102-104.
    Corominas-Faja, B; Cuyàs, E; Gumuzio, J; Bosch-Barrera, J; Leis, O; Martin, A.G; Menendez, J.A  "Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells."  Oncotarget  5 (2014):  8306-8316.
    Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Bruna Corominas-Faja, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Joaquim Bosch-Barr  "Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. ."  Food and Chemical Toxicology   (2013):  -.
    Sílvia Cufí; Rosa Bonavia; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Elisabet Cuyàs; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Joana Visa; Antonio Segura-Carretero; Jorge Joven; Joaqu  "Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. ."  Scientific Reports   (2013):  -.
    Alejandro Vazquez-Martin; Sílvia Cufí; Cristina Oliveras-Ferraros; Violeta Zenobia Torres-Garcia; Bruna Corominas-Faja; Elisabet Cuyàs; Rosa Bonavia; Joana Visa; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol  "IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. ."  Scientific Reports   (2013):  -.
    Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Menendez JA  "Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.."  Cell Cycle   (2013):  -.
    Castañon E; Bosch-Barrera J; López I; Collado V; Moreno M; López-Picazo JM; Arbea L; Lozano MD; Calvo A; Gil-Bazo I.  "Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. ."  Journal Of Translational Medicine  11 (2013):  -.
    Cristina Oliveras-Ferraros; Anna Massaguer Vall-Llovera; Alejandro Vazquez-Martin; Dolors Carrion Salip; Bernardo Queralt; Silvia Cufí; Begoña Martin-Castillo; Joaquim Bosch-Barrera; Joan Brunet; Rafael De Llorens; Javier A.   "Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.."  Oncology Reports  27 (2012):  1887-1892.
    Sílvia Cufí; Bruna Corominas-Faja; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Joan Dorca; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Javier A. Menendez  "Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts."  Oncotarget  4 (2012):  395-398.
    Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Menendez OJ; Bosch-Barrera J; Martin-Castillo B; Joven J; Menendez JA  "Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.."  Cell Cycle  11 (2012):  865-870.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Quirantes R; Segura-Carretero A; Micol V; Joven J; Bosch-Barrera J; Del Barco S; Martin-Castillo B; Vellon L; Menendez JA.  "Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205."  Cell Cycle  11 (2012):  1235-1246.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA  "Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. ."  British Journal of Cancer  106 (2012):  1406-1414.
    Bosch-Barrera J; García-Franco C; Guillén-Grima F; Moreno-Jiménez M; López-Picazo JM; Gúrpide A; Pérez-Gracia JL; Aristu J; Torre W; García-Foncillas J; Gil-Bazo I.  "The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.."  Clinical & Translational Oncology  14 (2012):  835-841.
    Bosch-Barrera J; Quer N; Brunet J  "Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective. ."  Clinical Lung Cancer  12 (2011):  335-340.
    Bosch-Barrera J; Espinós J.  "Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report.."  International Archives of Medicine  3 (2010):  1-3.
    Bosch-Barrera J; Urdiroz J; Centeno C  "Visual hallucinations and unusual pain related to hypomagnesemia in an advanced cancer patient ."  Anales del Sistema Sanitario de Navarra  33 (2010):  319-322.
    Bosch-Barrera J; Montero A; López-Picazo JM; García-Foncillas J; Ferrer M; Yuste JR; Gil-Bazo I.  "Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer."  Lung Cancer  64 (2009):  124-126.
    Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I  "Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.."  Onkologie  32 (2009):  580-584.
    Bosch-Barrera J; Arbea L; García-Velloso MJ; Gil-Bazo I; García-Foncillas J; Panizo C  "Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.."  Cases Journal  2 (2009):  1-5.
    Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J  "Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.."  Clinical & Translational Oncology  11 (2009):  765-767.


    Notes breus
    Bosch-Barrera J; Gil-Bazo I.  "Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany ."  Lung Cancer  71 (2011):  244-244.


    Review (Ressenyes i Recensions)
    Isla D; Afonso R; Bosch-Barrera J; Martínez N.  "Zoledronic acid in lung cancer with bone metastases: a review. ."  Expert Review Of Anticancer Therapy  13 (2013):  421-426.
    Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C  "Direct antitumour activity of zoledronic acid: preclinical and clinical data."  Clinical & Translational Oncology  13 (2011):  148-155.
    Bosch-Barrera J  "Ethical dilemmas in the medical practice in 2010: reflexions around the results of a survey to 10,000 physicians ."  Cuadernos de Bioética  22 (2011):  113-118.
    Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA.  "Metformin: multi-faceted protection against cancer.."  Oncotarget  2 (2011):  896-917.
    Bosch-Barrera J; Hernández A; Abella LE  "Insulin and insulin-like growth factor pathway, a new targeted therapy in oncology ."  Anales del Sistema Sanitario de Navarra  32 (2009):  413-421.
    Bosch Barrera, J.; López-Picazo González, JM.; García-Foncillas López, J.; Prósper Cardoso, F.  "Stem cells and cancer: elucidating the origin of the cancer stem cell."  Rev Med Univ Navarra  51 (2007):  14-17.



    Font de les dades: Sistema d'informació GREC